The Future Of CDMOs: Aseptic Filling Solutions For Growth And Innovation

By Josh Russell

The last four years have been a period of uncertainty and volatility worldwide. This has been especially true of the life science and biopharmaceutical industries, which have faced a period of extraordinary change and growth. An unprecedented number of people have been affected by illness and chronic disease, and there has never been a higher demand for targeted patient-centered treatments. And, just as vital, the tools and technology to meet that demand exist.

This new reality has also meant a change in orientation for the CMO/CDMO landscape. The rise of highly targeted cell and gene treatments requiring small batch production at a record pace requires a new path forward for biologics manufacturing. The demand represents good news: More and more people are getting life-improving and life-saving results from these innovative treatments. This also represents a high mandate for the pharmaceutical industry at large and for CMOs/CDMOs in particular. For CDMOs looking to meet the market demand, the considerations are many. Learn how AST is here to help.